Document:

Exhibit

Exhibit 10.1

Tennant Company
Executive Officer Cash Incentive Plan

1.   Purpose.  The purpose of the Tennant Company Executive Officer Cash Incentive Plan (the “Plan”) is to provide incentives to the management team of Tennant Company (the “Company”) and its subsidiaries to produce a superior return to the shareholders of the Company and to encourage such management team to make decisions based on the Company’s long-term success and successfully meet specified performance objectives.

2.   Definitions.  The terms defined in this section are used (and capitalized) elsewhere in the Plan.

“Award” means an award payable to a Participant pursuant to Section 4 hereof.

“Board” means the Board of Directors of the Company.

“Cause” shall mean termination for (i) the Participant’s material breach of any confidentiality, non-disclosure, non-solicitation, non-competition, invention assignment or similar agreement; (ii) an act or acts of dishonesty undertaken by the Participant and intended to result in gain or personal enrichment of the Participant at the expense of the Company; (iii) persistent failure by the Participant to perform the duties of the Participant’s employment, which failure is demonstrably willful and deliberate on the part of the Participant and constitutes gross neglect of duties by the Participant; or (iv) the indictment or conviction of the Participant for a felony if the act or acts constituting the felony are substantially detrimental to the Company or its reputation.

“Code” means the Internal Revenue Code of 1986, as amended.

“Committee” means the Compensation Committee or the Management Committee, as applicable.

“Compensation Committee” means the Compensation Committee of the Board or such other Board committee as may be designated by the Board to administer the Plan.

“Disability” means the disability of a Participant such that the Participant is considered disabled under any retirement plan of the Company which is qualified under Section 401 of the Code, or as otherwise determined by the Committee.

“Eligible Employee” means any member of the management team of the Company or a subsidiary thereof.

“Executive Officer” means anyone who is an executive officer under the rules and regulations of the Securities Exchange Act of 1934, as amended.

“Management Committee” means a committee consisting of one or more of the Company’s Chief Executive Officer, Vice President of Administration, Chief Financial Officer and such other senior management team member who supervises a Participant, as such committee is constituted from time to time and for such purposes, all as determined by the Chief Executive Officer.

“Participant” means an Eligible Employee designated by the Committee to participate in the Plan for a designated Performance Period.

1
US.118648969.02

“Performance Period” means the Company’s fiscal year or such other period, which may be shorter or longer than one fiscal year, designated by the Committee.

“Retirement” means termination of employment, other than by death or Disability or termination for Cause, on or after age 55, provided the Participant has been employed by the Company and/or one or more affiliates for at least ten years, or termination of employment, other than for death or Disability or termination for Cause, on or after age 62.

3.   Administration.    

3.1   Authority of Committee.  The Committee shall administer this Plan.  For all purposes under this Plan, the Committee shall refer to the Compensation Committee to the extent this Plan relates to Awards made to Executive Officers and shall refer to the Management Committee to the extent this Plan relates to Awards to Participants other than Executive Officers.  The Committee shall have exclusive power, subject to the limitations contained in this Plan, to make Awards and to determine when and to whom Awards will be granted, and the form, amount and other terms and conditions of each Award, subject to the provisions of this Plan.  The Committee shall have the authority to interpret and implement this Plan and any Award made under this Plan, to establish, amend, waive and rescind any rules and regulations relating to the administration of this Plan, and to make all other determinations necessary or advisable for the administration of this Plan.  The Committee may correct any defect, supply any omission or reconcile any inconsistency in this Plan or in any Award in the manner and to the extent it shall deem desirable.  The determinations of the Committee in the administration of this Plan, as described herein, shall be final, binding and conclusive, subject to the provisions of this Plan.  A majority of the members of the Committee shall constitute a quorum for any meeting of the Committee.

3.2   Indemnification.  To the full extent permitted by law, (i) no member or former member of the Committee shall be liable for any action or determination taken or made in good faith with respect to the Plan or any Award made under the Plan, and (ii) the members or former members of the Committee shall be entitled to indemnification by the Company against and from any loss incurred by such members by reason of any such actions and determinations.

4.   Awards.    

4.1   Allocation of Awards.  The Committee may select such Eligible Employees as they deem appropriate to participate in the Plan.  Eligible Employees selected to participate will be entitled to receive an award of bonus compensation based on the levels of attainment of one or any combination of two or more performance measures selected by the Committee (each, a “Performance Measure”). Each Performance Measure may be expressed in absolute amounts, on a per share basis, as a growth rate, as a change from prior Performance Periods, relative to a designated peer group or index of comparable companies or as otherwise determined by the Committee, and any such Performance Measures may relate to one or any combination of two or more of corporate, group, unit, division, affiliate or individual performance.  

2
US.118648969.02

4.2   Attainment of Performance Measures.  The payment of an Award will be contingent upon the degree of attainment of such Performance Measures over the applicable Performance Period as are specified by the Committee.  The Committee may, in its discretion, modify the Performance Measures applicable to a Performance Period if it determines that as a result of changed circumstances, such modification is required to reflect the original intent of such Performance Measures.  Each Performance Measure may be adjusted if so determined by the Committee, to exclude the effects of extraordinary items, unusual or non-recurring events, changes in accounting principles, realized investment gains or losses, discontinued operations, acquisitions, divestitures, material restructuring or impairment charges and other items as the Committee determines to be required so that the operations results of the Company, group, unit, division or affiliate, as applicable, shall be computed on a comparative basis.

4.3   Discretion.  The Committee is authorized at any time during or after a Performance Period, in its sole and absolute discretion, to increase, reduce or eliminate an Award payable to any Participant for any reason, including changes in the position or duties of any Participant with the Company or any subsidiary of the Company during the Performance Period.

4.4   Payment of Awards.  Following the completion of each Performance Period, the Committee shall certify in writing the degree to which the Performance Measures were attained and the Awards payable to Participants.  Each Participant shall receive payment in cash within two and a half months after the completion of the Performance Period following the determination in respect thereof made pursuant to this Section 4.4.  If the terms of the Award so provide, the Award may be settled in equity securities issued under the Company’s then-effective stock incentive plan.

5.   Effective Date of the Plan.  The Plan shall become effective as of January 1, 2019.  The Plan shall remain in effect until it has been terminated pursuant to Section 8.

6.   Right to Terminate Employment.  Nothing in the Plan shall confer upon any Participant the right to continue in the employment of the Company or any subsidiary or affect any right which the Company or any subsidiary may have to terminate the employment of a Participant with or without cause.  Employment with the Company remains “at will,” which means that all aspects of the job, including employment by the Company, may be changed or terminated by the Company at any time with or without cause.  Likewise, the Participant may terminate employment with the Company.

7.   Tax Withholding.  The Company shall have the right to withhold from cash or stock payments under the Plan to a Participant or other person an amount sufficient to cover any required withholding taxes.

8.   Amendment, Modification and Termination of the Plan.  The Committee may at any time terminate, suspend, amend or modify the Plan and the terms and provisions of any Award to any Participant which has not been paid.  No Award may be granted during any suspension of the Plan or after its termination.

9.   Unfunded Plan.  The Plan shall be unfunded, and the Company shall not be required to segregate any assets that may at any time be represented by Awards under the Plan.  No Participant shall, by virtue of this Plan, have any interest in any specific assets of the Company or any of its direct or indirect subsidiaries.

3

US.118648969.02

10.   Other Benefit and Compensation Programs.  Neither the adoption of the Plan by the Committee nor its submission to the shareholders of the Company shall be construed as creating any limitation on the power of the Committee to adopt such other incentive arrangements as it may deem appropriate.  Payments received by a Participant under an Award made pursuant to the Plan shall not be deemed a part of a Participant’s regular recurring compensation for purposes of the termination, indemnity or severance pay law of any state and shall not be included in, nor have any effect on, the determination of benefits under any other employee benefit plan, contract or similar arrangement provided by the Company or any subsidiary unless expressly so provided by such other plan, contract or arrangement, or unless the Committee expressly determines otherwise.

11.   Termination of Employment.  Except as otherwise provided by the Committee, should a Participant’s employment terminate prior to the end of the Performance Period for any reason other than death, Disability or Retirement, the Participant will not be entitled to payment of an Award for the Performance Period.  Except as otherwise provided by the Committee, if a Participant’s employment with the Company terminates by reason of death, Disability or Retirement, a prorated payment will be made within two and a half months following the end of the Performance Period, based upon the time the Participant served during the Performance Period.  The Award will be based on the performance over the entire Performance Period.  In the event of termination of the Participant’s employment by reason of death, Disability or Retirement, any election to receive payout in the form of equity securities under the Company’s stock incentive plan shall be null and void.

12.   Change of Job Within Company.  A Participant who is promoted or demoted to a position with different Performance Measures or performance targets will have a prorated Award based upon the time served in each job during the Performance Period, provided at least 90 days was served in each job.  If a Participant is in a position for less than 90 days during the Performance Period, the Award is based on the Performance Measures and performance targets of the job served in the longest.  A Participant who changes jobs that is no longer eligible for this Plan retains the right to receive a prorated Award under the Plan based on the length of time as a Participant provided at least 90 days was served as a Participant.  Notwithstanding the foregoing, the Committee may provide for different treatment of job changes in an Award or otherwise by Committee action.  

13.   Governing Law.  To the extent that Federal laws do not otherwise control, the Plan and all determinations made and actions taken pursuant to the Plan shall be governed by the laws of the State of Minnesota and construed accordingly.

4
US.118648969.02Exhibit 10.8

Intellectual Property Portfolio
License Agreement

 

This agreement, dated as of February 1,2018 (the “Effective
date”) is by and between Loubert S. Suddaby, MD (“Licensor”) and Spinus, LLC (hereinafter referred to
as the “ Company”), collectively hereinafter referred to as the “Parties” and each hereinafter
referred to a “Party”).

Now therefore, in consideration of mutual promises,
agreements, covenant, undertakings and obligations set forth herein and for other good and valuable consideration, the Parties
hereto agree as follows:

ARTICLE 1 – DEFINITIONS

		1.1	Definitions. For the purpose of the Agreement, the definitions set forth below shall be applicable.

Affiliate – The term “Affiliate”
means with respect to any person or entity, any other person or entity directly or indirectly controlling, controlled by, or under
common control with, such person or entity at any time during the period for which the determination of affiliation is being made.
For purposes of the foregoing, “control” means that more than fifty percent (50%) of the outstanding shares of any
voting class of stock, general partnership interest or other voting equity or analogous interests of the one entity is owned by
another entity, or the existence of any other relationship between two entities which results in the direct or indirect effective
managerial control by one over the other, regardless of whether such managerial control is continuously exercised.

Applicable Law – The term “Applicable
Law” means all laws, ordinances, rules and regulations applicable to the Agreement of the activities contemplated hereunder.

Assigned Patents – The term “Assigned
Patents” means U.S. and foreign patents, patent applications and provisional patent applications pertaining to EXHIBIT A.

Consulting Agreement – The term
“Consulting Agreement” refers to the agreement between Licensor and the Company pursuant to which the Licensor agrees
to provide Services (as defined therein) to the Company in connection the Company’s efforts to develop ratcheting expandable
interbody fusion devices, and/or inflatable interbody fusion devices.

First Commercial Sale – The term
“First Commercial Sale” shall mean the first arm’s length sale by the Company and/or Company Affiliate to a third
party.

Licensed Patents – The term “Licensed
Patents” means the U.S. and foreign patents, patent applications and provisional patent applications listed on Exhibit A
hereto, and all continuations, continuations-in-part, divisions reissues and reexaminations of any of the foregoing, and any patents
that claim priority to any of them, and any patents which are or become foreign equivalents thereof.

Net Sales – The term “Net
Sales” for any period means gross sales of the product billed and shipped by the Company or its Affiliate anywhere in the
world, less given discounts.

Products – The term “Product”
or “Products” means mechanical or inflatable expandable interbody implants covered by a Licensed Patent or Assigned
Patent.

Valid Claim – The term “Valid
Claim” means a claim of a patent duly issued which has not been declared invalid or unenforceable in a final judgment from
which no appeal may be taken.

ARTICLE 2 – THE GRANT

2.1 Grant. Subject to the terms and conditions
hereof, Licensor hereby grants to the Company and its Affiliates, and the Company hereby accepts a worldwide nontransferable license,
royalty bearing right and license under the licensed Patents to evaluate, develop, test, conduct clinical, trials, obtaining government
approvals, make, have made, use, practice manufacture, have manufactured, sell, transfer or commercialize products with the understanding
that such rights to products listed in Section 2 of Exhibit A are exclusive whereas these rights are non-exclusive with respect
to products set out in Section 1 of Exhibit A. Except as explicitly granted herein, no rights are granted herein by implication,
estoppel or otherwise and all rights not explicitly granted are reserved.

2.2 Commercialization. If
the Company fails within three (3) years from the Effective Date for any reason other than delays due to regulatory review authorities
to sell Products, Licensor may, at its option, terminate the Agreement and the licenses granted herein by providing the Company
with notice of termination, which termination shall be effective immediately upon receipt.

2.3 Limitations and Obligations

(a) neither
Licensor nor the Company may, without consent of the other, act as a supplier of products to another party where such products
are to be labelled for sale under any name other than Licensor or the Company or their respective Affiliates.

(b) Obligation of
Affiliates. The Company agrees that it is legally and financially responsible for its obligations and the obligations of its Affiliates
arising under this Agreement.

ARTICLE 3 – CONSIDERATION

3.1 Consideration. The Parties have entered this
Agreement voluntarily, and as a matter of convenience have agreed that the total consideration to be paid by the Company for the
rights granted hereunder shall be the following.

(a) Royalties
on Net Sales of the Products occurring during the term of this Agreement, at a rate of seven per cent (7%) of such Net Sales.

(b) Royalties
pursuant to Section 3.1 (a) shall be for the life of the Product and shall be paid as long as said Product is sold by the Company
or its Affiliates.

(c) In
addition, the Company will pay the following license fees (“License Fees”) which will be non-refundable and
not credited against any Royalties due under this Agreement.

(d) Two
hundred fifty thousand dollars ($250,000) within one year of signing the Agreement.

The Parties represent and warrant that in entering
into this Agreement they have bargained at arm’s length, that the amounts paid hereunder or set in advance and are fair market
value for the services provided.

3.2 Royalty Accrual. Royalties pursuant to 3.1
shall accrue as when the Net Sale subject to such royalty is recorded by the Company, or its Affiliates, in accordance with the
definition of “Net Sale” and shall be paid to the Licensor in accordance with the provisions of Article 4 below.

ARTICLE 4 – REPORTS, PAYMENTS AND RECORDS

4.1 Reports. The Company agrees to deliver quarterly
written reports to Licensor for each quarterly period for which Royalties are payable pursuant to Article 3 above, within thirty
(30) days after the end of each period. The report shall set forth the number of products sold by the Company or its Affiliates
during such quarterly period, as determined by the Company in good faith, and, based and thereon, the calculation and amount of
Royalties payable to the Licensor with respect to such period pursuant to Article 3. All information contained in such quarterly
reports shall be treated as confidential by the Company subject to Article 5 and shall be subject to adjustment, pursuant to section
4.2 below, based upon any Examination and the results of the Company’s regular annual audit.

4.2 Payment and Records. Royalties payable pursuant
to Section 3.1 above for a reported period shall be due and payable, to the extent calculated and set forth in the corresponding
quarterly report delivered to Licensor pursuant to Section 4.1 simultaneously with the submission of such report. The full amount
of all Royalties, when due, shall be paid to Licensor by certified check or bank transfer. In order to enable an independent certified
public accounting firm (the “CPA Firm”) appointed by Licensor and reasonably acceptable the Company to verify
the proper determination of Royalties, the Company shall maintain records in sufficient detail to allow for such verification,
and, subject to Article 5 below and upon reasonable notice, allow the CPA Firm to examine the Company consolidated books and records,
and to the extent necessary the books and records of its Affiliates pertaining to Product sales subject to the Company Royalty
obligations hereunder (such examination, the “Examination”). Examinations shall occur during business hours,
and not more than once a year, and shall be solely for the purpose of verifying the calculation of Royalties due under the Agreement.
The CPA Firm shall furnish a copy of any Examination results to Licensor and the Company promptly after completion thereof, together
with all work papers. Any underpayment of Royalties due to Licensor will be rectified in thirty (30) days. The Company shall pay
the reasonable costs, fees and expenses of the CPA Firm that may otherwise be due and payable by the Licensor to the CPA Firm for
an examination conducted by it pursuant to this Section 4.2, if and only if as a result of such Examination it is determined that
the Company underpaid the total amount due to the Licensor, applicable to the period that was the subject of such Examination by
more than five percent (5%).

4.3 Late Payments. In the event that any amount
payable under this Agreement is not paid when due, the Company will also pay interest on such amount for the period from the date
the payment is actually made computed at the rate equal to two percent (2%) per month.

ARTICLE 5 – PROPRIETARY INFORMATION

5.1 Confidentiality. During
the term of this Agreement and for an additional five (5) years, each Party agrees to keep and maintain the terms of this Agreement
confidential, and to keep confidential and use solely insofar as permitted by the express terms of this Agreement any other non-public
information disclosed to or obtained from such Party by the other Parties in connection with this Agreement. Notwithstanding the
foregoing, it shall not be a breach of this Agreement (i) in the event an action by one Party is believed by the other Party to
be in breach of this Agreement, for the other Party to file under seal with the court in such action such terms of this Agreement
as are necessary in order to bring or defend such action, (ii) for each Party to share the terms of this Agreement with its counsel,
provided such counsel is or has been made aware of the obligations of confidentiality herein, (iii) for any Party to disclose such
information as may be required by law or court order, after first having given the other Party at least ten (10) days written notice
of such legal requirement or order of court and intent to disclose pursuant to said requirement or order and (iv) for each Party
to share the terms of this Agreement with any of its Representatives (as defined below), as such party reasonably deems necessary
based on a “need to know” assessment, provided that the disclosing Party prior to disclosure, shall obtain a binding
agreement of such Representatives requiring them to retain the disclosed terms in confidence according to confidentiality obligations
that are at least as stringent as those imposed herein. In the event of a breach of such agreement by a disclosing Party’s
Representatives, the other Party may request that such disclosing Party, at its expense, initiate and prosecute judicial proceedings
to enforce such agreement, to the extent there is a legally cognizable good faith basis to do so, and seek damages and injunctive
relief as may be suitable and subject to recovery, or assign to the other Party the right, at its expense, to pursue such enforcement,
damages and relief, and the disclosing Party shall comply with any such request. The term “Representative” includes
a Party’s and its Affiliates’ respective directors, officers, employees, agents, financial advisors, attorneys, insurers,
accountants and permitted assignees and sublicensees.

5.2 Survival. The provisions
of this Article 5 shall survive expiration or termination of this Agreement.

ARTICLE 6 – REGULATORY
INTERACTION AND INDEMIFICATION

6.1 Regulatory Interaction.
Interaction with regulatory agencies in any country, including but not limited to the FDA and any international regulatory agencies,
concerning Products manufactured or sold by the Company or its Affiliates shall be a matter for the sole discretion of, and shall
be conducted by or with authority from, the Company or its Affiliates.

6.2 Indemnification.

(a) subject to the fulfillment
by Licensor of its obligations pursuant to Section 6.3 below, the Company agrees to defend, indemnify and hold harmless Licensor,
its Affiliates and their respective officers, directors, employees, agents and representatives (collectively, “Licensor Indemnities,”
and each a “Licensor Indemnitee” from and against all damages, liabilities, claims (including, without limitation,
product liability claims), costs, charges, judgements and expenses (including reasonable attorneys’ fees and expenses incurred
by the Company in asserting such defense, but otherwise excluding fees and expenses incurred by the Company in asserting such defense,
but otherwise excluding fees and costs of attorneys retained by Licensor or any foregoing Licensor Indemnitee) (collectively, “Liabilities”),
to the extent such Liabilities are asserted against a Licensor Indemnitee by a third party and arise out of or result from (i)
a defect in the design or manufacture of a Product sold or otherwise distributed by the Company or its Affiliates or (ii) sale
or promotion of such a Product by the Company or its Affiliates, or (iii) a breach of any representation or warranty given to Licensor
by the Company pursuant to this Agreement; or (iv) a third party claim that the manufacture, use, sale, offer for sale or importation
of the Product infringes upon the patent of such a third party by reason of the Company’s exercise of any of the rights granted
by Licensor under this Agreement and in accordance with this Agreement;

(b) subject to the fulfillment
by the Company of its obligations pursuant to Section 6.3 below, Licensor agrees to defend, indemnify and hold harmless the Company,
its Affiliates and their respective officers, directors, employees, agents and representatives (collectively, the “Company
Indemnities”, and each a Company Indemnitee, from and against all damages, liabilities, claims (including, without limitation,
product liability claims), costs, charges, judgements and expenses (including reasonable attorney’s fees and expenses incurred
by Licensor in asserting such defense, but otherwise excluding fees and costs of attorneys retained by the Company or any foregoing
Company Indemnitee) (collectively “Liabilities”), to the extent such Liabilities are asserted against the Company Indemnitee
by a third party and arise out of or result from (i) a defect in the design or manufacture of a Product sold or otherwise distributed
by Licensor or its Affiliates or sublicensee through Licensor’s exercise of his rights hereunder, or (ii) sale or promotion
of such a Product by Licensor or its Affiliates, or sublicensee, or (iii) a breach of any representation or warranty given to the
Company by Licensor pursuant to this Agreement; or (iv) a third party claim that the manufacture, use, sale, offer for sale or
importation of the Product by Licensor or its Affiliates infringes upon the patent of such a third party.

6.3 Consequential Damages.
IN NO CASE, HOWEVER WHETHER AS A RESULT OF A BREACH OF CONTRACT, BREACH OR WARRANTY OR TORT (INCLUDING THE COMPANY’S OR LICENSOR’S
NEGLIGENCE OR STRICT LIABILITY) SHALL THE COMPANY OR LICENSOR BE LIABLE TO THE OTHER FOR

ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL
DAMAGES INCURRED BY THE OTHER, INCLUDING BUT NOT LIMITED TO ANY LOSS OF USE, INTERRUPTION OF BUSINESS, INJURY TO GOODWILL, OR LOSS
OF SALES OR LOST PROFITS.

ARTICLE 7 – REPRESENTATIONS
AND WARRANTIES

7.1 Representations and Warranties.
Each Party hereby represents and warrants to the other Party that

(a) he or it has full right,
power and authority to enter into and be bound by the terms and conditions of this Agreement, to transfer the rights and to carry
out their respective obligations under this Agreement, without the approval or consent of any other person, (b) the entering into
this Agreement, the transfer of rights and the carrying out of their respective obligations under this Agreement is not prohibited,
restricted or otherwise limited by any contract, agreement or understanding entered into by such Party, or by which such Party
is bound, with any other person, including without limitation, any governmental authority, (c) there is no contract, agreement
or understanding entered into by a Party, or by which such Party is bound, which is enforced, terminated or modified, would be
in derogation or, contrary to, or adversely affect the rights acquired or to be acquired by the other party hereunder, and (d)
there is no action or investigation pending or currently threatened against such Party which, if adversely determined, would restrict
or limit such Party’s right to enter into this Agreement, transfer the rights or carry out such Party’s obligations
under this Agreement. Licensor further represents and warrants that: (i) he is the sole and exclusive beneficial and legal owner
of all right, title and interest in the Licensed Patents listed in Exhibit A, (ii) the Licensed Patents listed in Exhibit A are
all the patents and applications owned by Licensor relating to the expandable intervertebral interbody fusion implants and all
patents and applications owned by Licensor relating to inflatable expandable interbody fusion implants; (iii) the Licensed Patents
listed in Exhibit A name the true and correct inventive entity (iv) the licensed or assigned patents listed in Exhibit A name the
products to be assigned or licensed in their entirety and this agreement in no way impugns or impedes the Licensor’s right
to continue to invent, patent, make, license or sell other devices or products not expressly listed in Exhibit A, even if such
products are deemed competitive so long as they are independent patents with distinct valid claims.

ARTICLE 8 – TERM AND TERMINATION

8.1 Term.
The term of this Agreement (the “Term”) shall commence upon the date hereof and shall continue until the last
date upon which Product sale ceases and all reasonably collectible Net Sales have been received. If, however, at any time either
Party (the “Breaching Party”) shall fail to comply in any material respect with any of the obligations hereunder,
the other Party (the “Other Party”)may terminate this Agreement upon thirty (30) days prior written notice of the
Breaching Party, if such failure is not cured within thirty (30) days after such notice, provided that, if such cure cannot be
accomplished within thirty (30) day period no such termination shall result and the period for such cure shall be extended as
long as the Breaching Party is diligently pursuing a cure thereof.

8.2 Reservation
of Rights. The Parties expressly reserve all rights and remedies at law and specifically but without limitation damages, injunctive
and other provisional relief.

ARTICLE 9 – RIGHTS AFTER
TERMINATION

9.1 Rights
After Termination.

(a) All obligations of the
Parties which accrue on or before the effective termination date shall be fully enforceable after termination.

(b) If
this Agreement terminates and as a result, thereof, the Company is required to cease making Products covered by the Licensed Patents,
the Company, may nonetheless, subject to the royalty provisions set forth herein, dispose of inventory of Products, complete any
Products in the process of manufacture, and utilize materials then on order to make and sell Products.

ARTICLE 10 – NOTICES

10.1 Notices. Any
notice required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested
or delivered by messenger or air courier (overnight fare prepaid), and all payments shall be delivered, to the party to whim such
notice or payment is required or permitted to be given at its address set forth as follows:

If given to Licensor, to:

Loubert
S. Suddaby

76 Tanglewood
Drive West

Orchard
Park, NY 14127

Email: loubert57@gmail.com

 

Or, if given
to the Company, to:

Spinus LLC

5227 W. Adams Ave, Apt 401

Temple,TX 76502-4853

Attention: Ron Oman

Email: Ron@spinusllc.com

 

Any such notice shall be considered
when delivered, as indicated by signed receipt or other written delivery record, and absent such receipt, or record, such delivery
shall be deemed to have occurred one business day after sending by messenger or courier and five business days after sending by
certified mail. A Party hereto may change that address to which notice to it is to be given by notice as provided herein.

ARTICLE 11 – GOVERNING
LAW – ATTORNEY’ FEES

11.1 Governing Law and
Forum. This Agreement shall be construed and enforced in accordance with the internal laws of the State of Delaware.

11.2 Attorneys’
Fees. In any action brought by either Party against the other to enforce this Agreement, the prevailing party shall be entitled
to reimbursement of all costs and expenses (including reasonable attorneys’ fees) incurred in connection with such enforcement
action.

11.3 Patent Maintenance
Fees. The company agrees to pay all costs pertinent to the maintenance of the licensed or assigned patents.

IN WITNESS WHEREOF, the
Parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

 

	Loubert S. Suddaby, MD	Spinus LLC
	 	 
	 	 
	 	
	_________________________	 	BY:______________________	 
	 	 	       Ron Oman, Manager	 

 

 

 

    	 	 	 

     

    

 

EXHIBIT A

 

1. LICENSED PATENTS
(NON-EXCLUSIVE)

1.1  RATCHETING
EXPANDABLE TECNOLOGY

	PATENT NUMBER	 	TITLE	 	STATUS
	 	 	 	 	 
	7,044,971	 	Lordotic Fusion Implant	 	Issued
	US52206/0167547	 	Expandable Intervertebral Fusion Implant Having Hinged Walls	 	Pending
	6,183,517	 	Expandable Fusion Implant and Applicator	 	Issued
	6,174,334	 	Expandable Intervertebral Fusion Implant and Applicator	 	Issued
	6,159,244	 	Expandable Variable Angle Intervertebral Fusion Implant	 	Issued
	6,332,895	 	Expandable Intervertebral Fusion Implant Having Improved Stability	 	Issued
	EP 1139936	 	Expandable Intervertebral Fusion Implant	 	Issued
	EP 1301149	 	Expandable Intervertebral Fusion Implant Having Improved Stability	 	Issued

 

 

1.2  RACHETING CERVICAL TECNOLOGY

	PATENT NUMBER	 	TITLE	 	STATUS
	 	 	 	 	 
	6,328,738 B1

	 	Anterior Cervical Fusion Compression Plate and Screw Guide

	 	Issued

 

1.3  MIS (MINIMALLY INVASIVE SURGERY) FACET
FIXATION DEVICE

	PATENT NUMBER	 	TITLE	 	STATUS
	 	 	 	 	 
	8,080,046 B2

	 	Facet Joint Fixation Device

	 	Issued
	8,915,962 B1

	 	Facet Joint Fixation Device	 	Issued

 

2. LICENSED PATENTS (EXCLUSIVE)

	PATENT NUMBER	 	TITLE	 	STATUS
	 	 	 	 	 
	6,837,850 B2

	 	Percutaneous Tissue Dissection	 	Issued
	6,958,077 B2

	 	Inflatable Nuclear Prosthesis

	 	Issued
	6,969,405 B2

	 	Inflatable Intervertebral Disc Replacement Prosthesis

	 	Issued
	7,597,714 B2

	 	Inflatable Nuclear Prosthesis

	 	Issued
	7,914,534 B2

	 	Disk Preparation Tool

	 	Issued
	6,395,034 B1

	 	Intervertebral Disc Prosthesis

	 	Issued

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]